A new publication on aggressive breast cancers

Aggressive cancers such as triple-negative breast cancer and pancreatic adenocarcinoma continue to be associated with a poor prognosis due to their high invasiveness and the limited number of treatment options available.

In this study published in Molecular Therapy, Sébastien Jauliac’s group at the IRSL has identified an anti-tumour programme mediated by extracellular vesicles regulated by the transcription factor NFAT3.
This study shows that the anti-tumour activity of these vesicles is based on a combinatorial signature of 15 microRNAs, known as miR-Comb 15, capable of simultaneously targeting several molecular networks involved in tumour proliferation and invasion.

This approach illustrates the potential of combinatorial RNA therapies to address the biological complexity of cancers, going beyond the targeting of a single molecular alteration.

The research thus opens up new avenues for the development of therapeutic strategies based on extracellular vesicles as vectors for regulatory RNAs.

Congratulations to Guénolé Tossou, the first author, and to all the collaborators who contributed to this study.

See also the editorial ‘Fifteen miRNAs, one network: Rethinking single-target therapy for aggressive cancer’ published by Jürgen Wittmann in the same journal: https://www.cell.com/molecular-therapy-family/molecular-therapy/abstract/S1525-0016(26)00710-0

Enjoy the read!